

WHAT IS CLAIMED IS:

1. A method of immunizing a mammal less than 96 months of age against at least one infectious disease and at least one chronic immune-mediated disorder, comprising

administering to said mammal one or more pharmaceutically acceptable pharmaceutical preparations, comprising one or more immunogens, according to an immunization schedule according to which, at specific times after birth, the mammal receives one or more pharmaceutically acceptable doses of one or more immunogens;

said mammal thereby receiving, for each said infectious disease, a suitable immunogen in such amounts, given at such ages, as to be effective to substantially prevent or substantially reduce the severity of such infectious disease;

said administering further resulting in an immune response in said mammal sufficient to substantially reduce the incidence or severity of at least one chronic immune-mediated disorder in such mammals;

the first dose of said immunization schedule beginning before 42 days after birth, and said one or more immunogens acting to substantially reduce said chronic immune mediated disorder include at least one immunogen other than BCG.

2. The method of claim 1 where said mammal is not immunized with an immunogen in such amounts and at such times as ~~that~~ *autoimmune disease* would substantially induce said ~~immune-mediated disorder~~.

3. The method of claim 1 where, when all of the immunogens administered are selected from the group consisting of BCG, diphtheria, tetanus, pertussis, polio, hepatitis B, hemophilus influenza, measles, mumps and rubella immunogens, for at least one such immunogen, either

a

E

 sub
B
90

slb
B' cont
(a) a plurality of doses of the immunogen are administered, and such doses are administered less than 28 days apart, or

(b) the immunogen is a live polio virus and at least five doses are given during the first 112 days after birth, or

5 (c) the immunogen is not a live polio virus, and at least four doses are given during the first 112 days after birth.

a 5. The method of claim 1 wherein at least one immunogen other than a diphtheria, tetanus, pertussis, polio, hepatitis B, hemophilus influenza, measles, mumps and rubella immunogen is administered.

10 6. The method of claim 5 wherein one immunogen other than a BCG, diphtheria, tetanus, pertussis, polio, hepatitis B, hemophilus influenza, measles, mumps and rubella, influenza, cholera, BCG, plague, pneumococcus, neisseria, varicella, rabies, typhoid and yellow fever immunogen is administered.

a 7. The method of claim 1 wherein for at least one such immunogen, the total dosage during the first 112 days after birth is substantially greater than that required for immunization against the infectious disease with which it is associated.

a 20 8. The method of claim 1 wherein said at least one immunogen other than BCG is one other than a small pox immunogen.

a 9. The method of claim 1 wherein the first dose is administered before 28 days after birth.

B 10. The method of claim 1 wherein said immunogens are non-living.

a 11. The method of claim 1 in which the immunogens are administered parenterally.

a 12. The method of claim 1 in which the reduction in

91

- ⁹¹
~~diabetes~~ autoimmune disease
E D incidence of the disorder is at least 10%.
a 13%. The method of claim ¹³ in which the reduction in
E D incidence of the disorder is at least about 50%.
a 14%. The method of claim ¹³ in which the reduction in
E D incidence of the disorder is at least about 20%.
a 15%. The method of claim ¹³ in which said mammal is of a
population in which the normal incidence of the disorder is at
least 5.8 per 100,000 individuals of 0-14 years of age, said
incidence being standardized for age and sex.

a 10 15. A method according to claim ³ 1, wherein said chronic
immune mediated disorder is selected from the group consisting
of an autoimmune disease, asthma/allergy, and an immune mediated
cancer.

a H D 16. ^{The} method according to claim ¹³ 1, wherein said chronic
15 D ~~immune mediated disorder is~~ diabetes mellitus. ^{p decreased}

a H 17. ^{The} method according to claim ¹³ 1, wherein said mammal is
a human.

a H 18. ^{The} method according to claim ¹³ 1, wherein at least one of
said immunogens is an immunogen selected from the group
20 consisting of an anthrax immunogen, a small pox immunogen, a
pneumococcal immunogen, a cholera immunogen, a varicella
immunogen, a typhoid immunogen, a yellow fever immunogen, a
neisseria immunogen, a plague immunogen, an influenza immunogen,
a herpes immunogen, a meningitis immunogen, an adenovirus
25 immunogen, ~~a malaria immunogen, an HIV immunogen,~~ a
cytomegalovirus immunogen, a hepatitis C immunogen, rabies and
a molecule that cross reacts to any of said immunogens.

19. An immunogenic agent comprising a plague or anthrax
immunogen and at least one other immunogen corresponding to a

different organism or disease selected from the group consisting of a diphtheria immunogen, a tetanus immunogen, a pertussis immunogen, a hemophilus influenza immunogen, a hepatitis B immunogen, a polio immunogen, a measles immunogen, a mumps immunogen, a rubella immunogen, a varicella immunogen, a pneumococcal immunogen, a neisseria immunogen, a influenza immunogen, a cholera immunogen, a typhoid immunogen, a small pox immunogen, a anthrax immunogen, a plague immunogen, a herpes immunogen, a meningitis immunogen, an adenovirus immunogen, a malaria immunogen, an HIV immunogen, a cytomegalovirus immunogen, a hepatitis C immunogen, a rabies immunogen and a molecule that cross reacts immunologically to at least one of said immunogens.

20. A kit comprising a first receptacle holding plague or anthrax immunogen and a second receptacle holding at least one other immunogen corresponding to a different organism or disease selected from the group consisting of diphtheria immunogen, a tetanus immunogen, a pertussis immunogen, a hemophilus influenza immunogen, a hepatitis B immunogen, a polio immunogen, a measles immunogen, a mumps immunogen, a rubella immunogen, a varicella immunogen, a pneumococcal immunogen, a neisseria immunogen, a influenza immunogen, a cholera immunogen, a typhoid immunogen, a small pox immunogen, a anthrax immunogen, a plague immunogen, a herpes immunogen, a meningitis immunogen, an adenovirus immunogen, a malaria immunogen, an HIV immunogen, a cytomegalovirus immunogen, a hepatitis C immunogen, a rabies immunogen, and a molecule that cross reacts immunologically to at least one of said immunogens.

21. In a method for ~~pediatric~~ immunization against at least three infectious diseases, comprising administering at least one

a
ch
B2

pharmaceutically acceptable dose of diphtheria/ tetanus/pertussis vaccine to a mammal of at least 42 days of age, the improvement comprising

(a) further administering to said mammal at least one pharmaceutically acceptable dose of diphtheria/pertussis/ tetanus vaccine, wherein said further administration (a) is according to at least one step selected from the group consisting of

(1) administering at least two doses of said diphtheria/tetanus/pertussis vaccine at less than 42 days of age of said mammal;

(2) administering said at least one of said dose of said diphtheria/tetanus/pertussis vaccine at less than 42 days of age of said mammal and also administering at least a second dose of said diphtheria/tetanus/pertussis vaccine, said second dose or any subsequent dose administered less than 28 days after the preceding dose when said mammal is less than 175 days of age; and

(3) administering said at least one dose of said diphtheria/tetanus/pertussis vaccine at less than 42 days of age of said mammal and also administering as a total of at least four doses of said diphtheria/tetanus/pertussis vaccine prior to the age of 112 days of said mammal,

wherein the further administration reduces at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder, or at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

22. The method of claim 21 wherein said further

administration

MINIMAL 4
 5 ~~for comprises further administering to said ^{mammal, at} ~~mammal of at~~~~
 least 28 days of age but less than 175 days of age, ~~at least one~~
~~pharmaceutically acceptable dose of at least one pharmaceutically~~
~~acceptable immunogen,~~

sub C1 cont
 10 ~~wherein said at least one dose comprises~~ a total of at least 4
 separate pharmaceutically acceptable doses of at least one
 pharmaceutically acceptable immunogen from the group consisting
 of a diphtheria/tetanus/pertussis immunogen, a hepatitis B
 immunogen, a hemophilus influenza immunogen, a
 measles/mumps/rubella immunogen, a polio immunogen, and a non-
 pediatric immunogen, administered to said mammal during said
 ages, at least 2 of said at least 4 doses ^{being} ~~provided~~ prior to the
 age of 112 days of said mammal, and wherein the further
 15 administration reduces at least one measure selected from the
 group consisting of incidence, prevalence, frequency, and
 severity of at least one chronic immune mediated disorder, or at
 least one surrogate marker of said disorder, in a population and
 or subpopulation of said mammals.

a 20 23. In a method for ~~pediatric~~ immunization against at least
 two infectious diseases, comprising administering at least one
 pharmaceutically acceptable dose of diphtheria/tetanus/pertussis
sub B3
 25 vaccine and at least one pharmaceutically acceptable dose of
 hemophilus influenza vaccine to a mammal of at least 42 days of
 age, the improvement comprising

(a) further administering to said mammal at least one
 pharmaceutically acceptable dose of at least one of a
 diphtheria/pertussis/tetanus vaccine and a hemophilus influenza
 vaccine wherein said further administration (a) is according to

at least one method from the group consisting of

(1) administrating at least one dose of both said diphtheria/pertussis/tetanus vaccine and said hemophilus influenza vaccine at less than 42 days of age of said mammal and at least a second dose of at least one said vaccine prior to 42 days of age of said mammal;

(2) administering at least one of said dose of both said diphtheria/tetanus/pertussis vaccine and said hemophilus influenza vaccine at less than 42 days of age of said mammal and also administering at least a second dose of both of said vaccines, wherein said second dose and or any subsequent dose is administered at less than 42 days after the preceding dose when said mammal is less than 175 days of age; and

(3) administering at least one of said dose of both said diphtheria/tetanus/pertussis vaccine and said hemophilus influenza vaccine at less than 42 days of age of said mammal and administrating at least four doses, prior to the age of 112 days, of said mammal for said diphtheria/pertussis/ tetanus vaccine or said hemophilus influenza vaccine, wherein the further administration reduces at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder, or at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

24. In a method for ~~pediatric~~ immunization against at least two infectious diseases, comprising administering at least one pharmaceutically acceptable first dose of at least one pharmaceutically acceptable immunogen selected from the group consisting of a diphtheria/tetanus/pertussis immunogen, a polio

immunogen, a hepatitis B immunogen, a hemophilus influenza immunogen, a non-pediatric immunogen, and a measles/mumps/rubella immunogen, to a mammal after 112 days of age but prior to 724 days of age, the improvement comprising

5 (a) further administering to said mammal, prior to the age of 112 days, at least one pharmaceutically acceptable second dose containing a greater amount of said immunogen than the amount of immunogen administered as said first dose after 112 days of age but prior to 724 days of age of said mammal, wherein the further administration reduces at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder, or at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

10 25. In a method for ~~pediatric~~ immunization against at least two infectious diseases, comprising administering at least one pharmaceutically acceptable dose of a non-whole cell pertussis vaccine to a mammal at least 42 days of age but prior to 724 days of age, the improvement comprising

15 20 (a) further administering to said mammal at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen selected from the group consisting of an diphtheria/tetanus immunogen, a non-whole cell pertussis immunogen, a whole cell pertussis immunogen, a polio immunogen, 25 a hemophilus influenza immunogen, a measles/mumps/rubella immunogen and a non-pediatric immunogen, wherein said further administration (a) is according to at least one selected from the group consisting of

(1) administrating said at least one dose of said

46B
B3
ACONT

immunogen at less than 42 days of age of said mammal;

(2) administering said at least one dose of said immunogen, said dose comprising at least a second dose, said second dose or any subsequent said dose administered less than 28 days after the preceding dose when said mammal is less than 175 days of age; and

(3) administering at least four doses prior to the age of 112 days of said mammal, wherein the further administration reduces at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder, or at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

26. In a method for ~~pediatric~~ immunization against at least two infectious diseases, comprising administering at least one pediatric vaccine to a mammal of at least 42 days of age, the improvement comprising

(a) further administering to said mammal at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable vaccine selected from (i) a combined vaccine containing at least diphtheria, tetanus, pertussis, and hemophilus influenza immunogens, and (ii) a combined vaccine containing at least diphtheria, tetanus, pertussis, and hepatitis B immunogens,

wherein said further administration (a) is according to at least one step selected from the group consisting of

(1) administering at least one of said dose of said combined vaccine at less than 42 days of age of said mammal;

(2) administering at least one of said dose of said

10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562
 563
 564
 565
 566
 567
 568
 569
 570
 571
 572
 573
 574
 575
 576
 577
 578
 579
 580
 581
 582
 583
 584
 585
 586
 587
 588
 589
 590
 591
 592
 593
 594
 595
 596
 597
 598
 599
 600
 601
 602
 603
 604
 605
 606
 607
 608
 609
 610
 611
 612
 613
 614
 615
 616
 617
 618
 619
 620
 621
 622
 623
 624
 625
 626
 627
 628
 629
 630
 631
 632
 633
 634
 635
 636
 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658
 659
 660
 661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676
 677
 678
 679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711
 712
 713
 714
 715
 716
 717
 718
 719
 720
 721
 722
 723
 724
 725
 726
 727
 728
 729
 730
 731
 732
 733
 734
 735
 736
 737
 738
 739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751
 752
 753
 754
 755
 756
 757
 758
 759
 760
 761
 762
 763
 764
 765
 766
 767
 768
 769
 770
 771
 772
 773
 774
 775
 776
 777
 778
 779
 780
 781
 782
 783
 784
 785
 786
 787
 788
 789
 790
 791
 792
 793
 794
 795
 796
 797
 798
 799
 800
 801
 802
 803
 804
 805
 806
 807
 808
 809
 810
 811
 812
 813
 814
 815
 816
 817
 818
 819
 820
 821
 822
 823
 824
 825
 826
 827
 828
 829
 830
 831
 832
 833
 834
 835
 836
 837
 838
 839
 840
 841
 842
 843
 844
 845
 846
 847
 848
 849
 850
 851
 852
 853
 854
 855
 856
 857
 858
 859
 860
 861
 862
 863
 864
 865
 866
 867
 868
 869
 870
 871
 872
 873
 874
 875
 876
 877
 878
 879
 880
 881
 882
 883
 884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899
 900
 901
 902
 903
 904
 905
 906
 907
 908
 909
 910
 911
 912
 913
 914
 915
 916
 917
 918
 919
 920
 921
 922
 923
 924
 925
 926
 927
 928
 929
 930
 931
 932
 933
 934
 935
 936
 937
 938
 939
 940
 941
 942
 943
 944
 945
 946
 947
 948
 949
 950
 951
 952
 953
 954
 955
 956
 957
 958
 959
 960
 961
 962
 963
 964
 965
 966
 967
 968
 969
 970
 971
 972
 973
 974
 975
 976
 977
 978
 979
 980
 981
 982
 983
 984
 985
 986
 987
 988
 989
 990
 991
 992
 993
 994
 995
 996
 997
 998
 999
 1000
 1001
 1002
 1003
 1004
 1005
 1006
 1007
 1008
 1009
 1010
 1011
 1012
 1013
 1014
 1015
 1016
 1017
 1018
 1019
 1020
 1021
 1022
 1023
 1024
 1025
 1026
 1027
 1028
 1029
 1030
 1031
 1032
 1033
 1034
 1035
 1036
 1037
 1038
 1039
 1040
 1041
 1042
 1043
 1044
 1045
 1046
 1047
 1048
 1049
 1050
 1051
 1052
 1053
 1054
 1055
 1056
 1057
 1058
 1059
 1060
 1061
 1062
 1063
 1064
 1065
 1066
 1067
 1068
 1069
 1070
 1071
 1072
 1073
 1074
 1075
 1076
 1077
 1078
 1079
 1080
 1081
 1082
 1083
 1084
 1085
 1086
 1087
 1088
 1089
 1090
 1091
 1092
 1093
 1094
 1095
 1096
 1097
 1098
 1099
 1100
 1101
 1102
 1103
 1104
 1105
 1106
 1107
 1108
 1109
 1110
 1111
 1112
 1113
 1114
 1115
 1116
 1117
 1118
 1119
 1120
 1121
 1122
 1123
 1124
 1125
 1126
 1127
 1128
 1129
 1130
 1131
 1132
 1133
 1134
 1135
 1136
 1137
 1138
 1139
 1140
 1141
 1142
 1143
 1144
 1145
 1146
 1147
 1148
 1149
 1150
 1151
 1152
 1153
 1154
 1155
 1156
 1157
 1158
 1159
 1160
 1161
 1162
 1163
 1164
 1165
 1166
 1167
 1168
 1169
 1170
 1171
 1172
 1173
 1174
 1175
 1176
 1177
 1178
 1179
 1180
 1181
 1182
 1183
 1184
 1185
 1186
 1187
 1188
 1189
 1190
 1191
 1192
 1193
 1194
 1195
 1196
 1197
 1198
 1199
 1200
 1201
 1202
 1203
 1204
 1205
 1206
 1207
 1208
 1209
 1210
 1211
 1212
 1213
 1214
 1215
 1216
 1217
 1218
 1219
 1220
 1221
 1222
 1223
 1224
 1225
 1226
 1227
 1228
 1229
 1230
 1231
 1232
 1233
 1234
 1235
 1236
 1237
 1238
 1239
 1240
 1241
 1242
 1243
 1244
 1245
 1246
 1247
 1248
 1249
 1250
 1251
 1252
 1253
 1254
 1255
 1256
 1257
 1258
 1259
 1260
 1261
 1262
 1263
 1264
 1265
 1266
 1267
 1268
 1269
 1270
 1271
 1272
 1273
 1274
 1275
 1276
 1277
 1278
 1279
 1280
 1281
 1282
 1283
 1284
 1285
 1286
 1287
 1288
 1289
 1290
 1291
 1292
 1293
 1294
 1295
 1296
 1297
 1298
 1299
 1300
 1301
 1302
 1303
 1304
 1305
 1306
 1307
 1308
 1309
 1310
 1311
 1312
 1313
 1314
 1315
 1316
 1317
 1318
 1319
 1320
 1321
 1322
 1323
 1324
 1325
 1326
 1327
 1328
 1329
 1330
 1331
 1332
 1333
 1334
 1335
 1336
 1337
 1338
 1339
 1340
 1341
 1342
 1343
 1344
 1345
 1346
 1347
 1348
 1349
 1350
 1351
 1352
 1353
 1354
 1355
 1356
 1357
 1358
 1359
 1360
 1361
 1362
 1363
 1364
 1365
 1366
 1367
 1368
 1369
 1370
 1371
 1372
 1373
 1374
 1375
 1376
 1377
 1378
 1379
 1380
 1381
 1382
 1383
 1384
 1385
 1386
 1387
 1388
 1389
 1390
 1391
 1392
 1393
 1394
 1395
 1396
 1397
 1398
 1399
 1400
 1401
 1402
 1403
 1404
 1405
 1406
 1407
 1408
 1409
 1410
 1411
 1412
 1413
 1414
 1415
 1416
 1417
 1418
 1419
 1420
 1421
 1422
 1423
 1424
 1425
 1426
 1427
 1428
 142

combined vaccine, said dose comprising at least a second dose, said second dose or any subsequent dose administered less than 28 days after the preceding dose when said mammal is less than 175 days of age; and

5 (3) administrating at least four doses prior to the age of 112 days of said mammal, wherein the further administration reduces at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated
10 disorder, or at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

27. In a method of for ~~pediatric~~ immunization against at least two infectious diseases and tolerizing against at least one antigen, comprising administering at least one pharmaceutically acceptable dose of at least one pediatric vaccine to a mammal of at least 42 days of age and administering at least one tolerogen to said mammal,
the improvement comprising

(a) further administering to said mammal at least one
20 pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen selected from the group consisting of an diphtheria/tetanus/ptussis immunogen, a hemophilus influenza immunogen, a measles/mumps/rubella immunogen, a polio immunogen, and a non-pediatric immunogen,

25 wherein said further administration (a) is according to at least one step selected from the group consisting of

(1) administrating said at least one dose of said immunogen at less than 42 day of age of said mammal;

(2) administering said at least one dose of said

a
cls
B3
cont

immunogen, said dose comprising at least a second dose, said
 second dose or any subsequent dose administered less than 28 days
 after the preceding dose when said mammal is less than 175 days
 of age; and

(3) administering at least four doses prior to the
 age of 112 days of said mammal,
 wherein the further administration reduces at least one measure
 selected from the group consisting of incidence, prevalence,
 frequency, and severity of at least one chronic immune mediated
 disorder, or at least one surrogate marker of said disorder, in
 a population and or subpopulation of said mammals.

28. In a method for ~~pediatric~~ immunization against at least
 two infectious diseases, comprising administering at least one
 pharmaceutically acceptable dose of at least one pediatric
 vaccine to a mammal of at least 42 days of age,
 the improvement comprising

(a) further administering to said mammal at least one
 pharmaceutically acceptable suprainmunogenic dose of at least one
 pharmaceutically acceptable vaccine prior to the age of 112 days
 of said mammal,

wherein the further administration reduces at least one measure
 selected from the group consisting of incidence, prevalence,
 frequency, and severity of at least one chronic immune mediated
 disorder, or at least one surrogate marker of said disorder, in
 a population and or subpopulation of said mammals.

25. A method according to claim 28, wherein said at least
 one suprainmunogenic dose comprises at least a second dose, said
 second dose or any subsequent suprainmunogenic dose is
 administered less than 28 days after the preceding dose when said

93

mammal is less than 175 days of age.

30. In a method for ~~pediatric~~ immunization against at least two infectious diseases, comprising administering at least one pharmaceutically acceptable dose of at least one pediatric vaccine to a mammal of at least 42 days of age,

the improvement comprising

(a) further administering to said mammal at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen to said mammal prior to the age of 8 days;

and

(b) further administering at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen to said mammal at least 11 days of age but less than 26 days of age,

wherein the further administrations reduce at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder, or at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

(c) ²⁸ The method according to claim ²⁷ ~~30~~, further comprising: additionally administering at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen at least 11 days, but less than 26 days, after the last dose of said immunogen ^{preceding} ~~preceding~~ 26 days of age of said mammal.

(d) ²⁹ The method according to claim ²⁸ ~~31~~, further comprising: administering at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen at least 11 days, but less than 26 days, after said additional

94

B.
a administration, of step (c).

33. In a method for ~~pediatric~~ immunization against at least two infectious diseases, comprising administering at least one pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen to a mammal, the improvement comprising

sub 5 (A) further administering at least a second pharmaceutically acceptable dose of at least one pharmaceutically acceptable immunogen, said second dose and or any subsequent dose is administered less than 28 days after the preceding dose, wherein said (i) second or any subsequent dose contains the same or different immunogens or the same or different amounts of said immunogens as any other dose; (ii) each said separate dose is administered during a 0-78 hour period, and (iii) the further administration reduces at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder, or at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

20 34. A method according to claim 33, wherein the total number of said separate doses is at least 4 prior to 112 days of age of said mammal.

35. In a method for ~~pediatric~~ immunization against at least two infectious diseases, comprising administering at least one pharmaceutically acceptable dose of hepatitis B vaccine to a mammal of at least 42 days of age, the improvement comprising

sub B4 (a) further administering to said mammal at least one pharmaceutically acceptable dose of said hepatitis B vaccine

95

according to at least one step selected from the group consisting of

(1) administering at least 3 said doses of said vaccine at less than 56 days of age of said mammal;

(2) administering said at least one dose of said vaccine, said dose comprising at least a second dose, said second dose or any subsequent dose administered less than 28 days after the preceding dose when said mammal is less than 175 days of age; and

(3) administering at least four doses prior to the age of 112 days of said mammal, wherein the further administration reduces at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder, or of at least one surrogate marker of said disorder, in a population and or subpopulation of said mammals.

36. A method of screening at least one potentially pharmaceutically acceptable dose of at least two potentially pharmaceutically acceptable immunogenic agents which comprise at least one potentially pharmaceutically acceptable first pediatric immunogen and at least one agent selected from the group consisting of a second pediatric immunogen and a non-pediatric immunogen, for the ability to modulate the development of at least one chronic immune mediated disorder, or at least one surrogate marker of said chronic immune mediated disorder, in a population and or subpopulation of said mammals, said method comprising

(a) administering, to at least one treatment group of at least one mammal at risk for at least one said chronic immune

mediated disorder, at least one treatment dose of said immunogenic agents according to a treatment administration schedule, said at least one treatment dose comprising at least a first treatment dose of at least one of said immunogenic agents administered prior to an age of 56 days of said mammal;

(b) optionally defining one or more control groups of at least one said mammal, wherein said control group receives at least one control dose which contains at least one potentially pharmaceutically acceptable pediatric immunogen and has at least one modification selected from the group consisting of:

(i) lacking at least one immunogenic agent/adjuvant than as is provided in said treatment schedule;

(ii) including at least one immunogenic agent/adjuvant than as is provided in said treatment schedule;

(iii) including a higher dose of at least one immunogenic agent/adjuvant than as is provided in said treatment schedule;

(iv) including a lower dose of at least one immunogenic agent/adjuvant than as is provided in said treatment schedule;

(v) including at least one additional dose of at least one immunogenic agent/adjuvant than as is provided in said treatment schedule;

(vi) lacking at least one dose of at least one immunogenic agent/adjuvant than as is provided in said treatment schedule;

(vii) including at least one dose of at least one immunogenic agent/adjuvant at a later time than said immunogenic agent/adjuvant is administered in said treatment schedule;

(viii) including at least one dose of at least one

immunogenic agent/adjuvant at an earlier time than said immunogenic agent/adjuvant is administered in said treatment schedule; and

(ix) no modifications from said treatment schedule wherein at least one measure selected from the group consisting of incidence, prevalence, frequency, and severity of at least one chronic immune mediated disorder or at least one surrogate marker of said disorder, is potentially or actually determined in said control group;

(c) determining the modulation of development of said at least one chronic immune mediated disorder by at least one of said treatment administration schedule,

wherein said determining step (c) comprises ascertaining at least one measure selected from the group consisting of incidence, prevalence, frequency and severity of at least one chronic immune mediated disorder, or at least one surrogate marker of said disorder, in at least one mammal in said at least one treatment group and, optionally, said measures in at least one mammal in said one or more control groups.

37. A method of immunizing a mammal less than 96 months of age against at least two infectious disease and at least one chronic immune-mediated disorder, comprising

administering to said mammal one or more pharmaceutically acceptable pharmaceutical preparations, comprising one or more immunogens, according to an immunization schedule according to which, at specific times after birth, the mammal receives one or more pharmaceutically acceptable doses of one or more immunogens;

said mammal thereby receiving, for each said infectious disease, a suitable immunogen in such amounts, given at such

ages, as to be effective to substantially prevent or substantially reduce the severity of such infectious disease;

*Sub
B?
omit* said administering further resulting in an immune response in said mammal sufficient to substantially reduce the incidence or severity of at least one chronic immune-mediated disorder in such mammal;

the first dose of said immunization schedule including an immune modulator beginning before 42 days after birth,

where said mammal is not immunized with an immunogen in such 10 amounts and at such times as would substantially induce said immune-mediated disorder.

*add
D
add
E9*